Surmodics, Inc.
NASDAQ•SRDX
CEO: Mr. Gary R. Maharaj
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1998-03-04
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Contact Information
Market Cap
$392.25M
P/E (TTM)
-22.2
vs Industry 44.7
Dividend Yield (TTM)
--
52W High
$40.39
52W Low
$26.00
52W Range
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$29.57M-2.55%
4-Quarter Trend
EPS
-$0.37-30.19%
4-Quarter Trend
FCF
$904.00K-130.21%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
$821.40M
KIDS$227.41M
KIDS$227.41M
Gross Margin (Latest Quarter)
91.0%
86.3%
TMCI79.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VREX | $485.15M | -3.7 | -25.5% | 2.3% |
| BNTC | $429.46M | -15.6 | -45.3% | 0.9% |
| KIDS | $422.30M | -8.6 | -13.0% | 9.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
-3.8%
Flat Growth
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Jun 30, 2025|Filed: Aug 8, 2025|Revenue: $29.57M-2.6%|EPS: $-0.37-30.2%MissForm 10-Q - Q2 2025
Period End: Mar 31, 2025|Filed: Apr 30, 2025|Revenue: $28.09M-12.1%|EPS: $-0.36-2157.1%MissForm 10-Q - Q1 2025
Period End: Dec 31, 2024|Filed: Jan 30, 2025|Revenue: $29.92M-2.1%|EPS: $-0.26+366.8%MissForm 10-K - FY 2024
Period End: Sep 30, 2024|Filed: Nov 20, 2024|Revenue: $126.08M-4.9%|EPS: $-0.82-645.5%MissForm 10-Q - Q3 2024
Period End: Jun 30, 2024|Filed: Jul 31, 2024|Revenue: $30.34M-42.2%|EPS: $-0.53-201.9%MissForm 10-Q - Q2 2024
Period End: Mar 31, 2024|Filed: May 1, 2024|Revenue: $31.96M+17.5%|EPS: $0.02-103.2%BeatForm 10-Q - Q1 2024
Period End: Dec 31, 2023|Filed: Feb 1, 2024|Revenue: $30.55M+22.5%|EPS: $-0.06-90.1%BeatForm 10-K - FY 2023
Period End: Sep 30, 2023|Filed: Nov 22, 2023|Revenue: $132.58M+32.6%|EPS: $-0.11+94.4%Miss